Drug intelligence / Profile preview

Celleks

Development stage: Unknown
Lead developer: Pharm-Sintez
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Subcutaneous

Overview

Celleks is a neuroprotective biologic developed by Pharm-Sintez, consisting of a balanced mixture of biologically active proteins and polypeptides derived from embryonic pig brain tissue. It is approved in Russia for the treatment of cerebrovascular diseases, specifically acute disorders of cerebral circulation such as ischemic stroke. The drug's mechanism of action involves a multi-component effect on neuroprotection, neuroregeneration, and neuroplasticity by providing growth factors and signaling molecules that support neuronal survival and differentiation. It is administered via subcutaneous injection.

Brand names: Celleks
Other names: CellexЦеллекс

Beyond the preview

Go deeper on Celleks.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celleks.

Explore the full profile